A major step forward has been made in predicting how well melanoma patients would respond to treatment, thanks to ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have ...

The decision to choose systemic adjuvant therapy warrants careful discussion on its benefits and risks,” researchers wrote.

Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

In January 2025, Melanoma Institute Australia announced a phase II, open label, randomised trial of ipilimumab and nivolumab ...

1). RubrYc’s lead programs include RTX-002, an anti-PD-1 agonist for serious autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, and RTX-003, an anti-CD25 antibody ...